Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma

Journal of Clinical Oncology

Volumn 29, Issue 27, 2011, Pages 3611-3619

  Chiocca, E Antonio ^a   Aguilar, Laura K ^c   Bell, Susan D ^a   Kaur, Balveen ^a   Hardcastle, Jayson ^a   Cavaliere, Robert ^a   McGregor, John ^a   Lo, Simon ^a   Ray Chaudhuri, Abhik ^a   Chakravarti, Arnab ^a   Grecula, John ^a   Newton, Herbert ^a   Harris, Kimbra S ^b   Grossman, Robert G ^b   Trask, Todd W ^b   Baskin, David S ^b   Monterroso, Carissa ^c   Manzanera, Andrea G ^c   Aguilar Cordova, Estuardo ^c   New, Pamela Z ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c Advantagene Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLIATAK; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VALACICLOVIR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONFUSION; CONSTIPATION; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; FUNCTIONAL ASSESSMENT OF CANCER BRAIN; GENE VECTOR; GLIOBLASTOMA; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYDROCEPHALUS; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; INSOMNIA; LEG EDEMA; LEUKOPENIA; LIQUORRHEA; LYMPHOCYTIC INFILTRATION; NAUSEA AND VOMITING; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE RETENTION; WOUND;

ACYCLOVIR; ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; DACARBAZINE; GENE THERAPY; GENETIC VECTORS; GLIOMA; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; THYMIDINE KINASE; TREATMENT OUTCOME; VALINE;

EID: 80053061789     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.5222     Document Type: Article

References (60)

1. Stupp R, Mason WP, Van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
2. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
3. Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787, 2008
4. Yu JS, Liu G, Ying H, et al: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979, 2004 (Pubitemid 38924545)
5. Liau LM, Prins RM, Kiertscher SM, et al: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515-5525, 2005 (Pubitemid 41060828)
6. Vile RG, Castleden S, Marshall J, et al: Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 71:267-274, 1997 (Pubitemid 27253001)
7. Melcher A, Todryk S, Hardwick N, et al: Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 4:581-587, 1998 (Pubitemid 28237357)
8. Chhikara M, Huang H, Vlachaki MT, et al: Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol Ther 3:536-542, 2001 (Pubitemid 32509847)
9. Ayala G, Satoh T, Li R, et al: Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 13:716-728, 2006
10. Eastham JA, Chen SH, Sehgal I, et al: Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7:515-523, 1996 (Pubitemid 26079062)
11. Fyfe JA, Keller PM, Furman PA, et al: Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2- hydroxyethoxymethyl) guanine. J Biol Chem 253:8721-8727, 1978 (Pubitemid 9104655)
12. Freeman SM, Abboud CN, Whartenby KA, et al: The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53:5274-5283, 1993 (Pubitemid 23333399)
13. Fick J, Barker FG 2nd, Dazin P, et al: The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci U S A 92:11071-11075, 1995
14. Ram Z, Walbridge S, Shawker T, et al: The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of gliomas in rats. J Neurosurg 81:256-260, 1994
15. Perez-Cruet MJ, Trask TW, Chen SH, et al: Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res 39:506-511, 1994 (Pubitemid 24348304)
16. Hall SJ, Mutchnik SE, Chen SH, et al: Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 70:183-187, 1997 (Pubitemid 27107415)
17. Vile RG, Nelson JA, Castleden S, et al: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228-6234, 1994 (Pubitemid 24378658)
18. Kuriyama S, Kikukawa M, Masui K, et al: Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer 83:374-380, 1999 (Pubitemid 29455761)
19. Gagandeep S, Brew R, Green B, et al: Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect". Cancer Gene Ther 3:83-88, 1996 (Pubitemid 126732427)
20. Curtin JF, Liu N, Candolfi M, et al: HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 6:e10, 2009
21. Ramesh R, Munshi A, Abboud CN, et al: Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 3:373-384, 1996
22. Barba D, Hardin J, Sadelain M, et al: Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 91:4348-4352, 1994 (Pubitemid 24143430)
23. Ghulam Muhammad AK, Candolfi M, King GD, et al: Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: Humoral and cellular immunity lead to tumor regression. Clin Cancer Res 15:6113-6127, 2009
24. Colombo F, Barzon L, Franchin E, et al: Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: Biological and clinical results. Cancer Gene Ther 12:835-848, 2005 (Pubitemid 43086285)
25. Trask TW, Trask RP, Aguilar-Cordova E, et al: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 1:195-203, 2000
26. Herman JR, Adler HL, Aguilar-Cordova E, et al: In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial. Hum Gene Ther 10:1239-1249, 1999 (Pubitemid 29231866)
27. Miles BJ, Shalev M, Aguilar-Cordova E, et al: Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12:1955-1967, 2001 (Pubitemid 33116762)
28. Shalev M, Kadmon D, Teh BS, et al: Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 163:1747-1750, 2000 (Pubitemid 30366727)
29. Aguilar LK, Teh B, Mai W, et al: Five year follow up of a phase II study of cytotoxic immunotherapy combined with radiation in newly diagnosed prostate cancer. J Clin Oncol 24:250s, 2006 (suppl: abstr 4635)
30. Van der Linden RR, Haagmans BL, Mongiat- Artus P, et al: Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur Urol 48:153-161, 2005
31. Hasenburg A, Tong XW, Fischer DC, et al: Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol 83:549-554, 2001 (Pubitemid 33139718)
32. Chévez-Barrios P, Chintagumpala M, Mieler W, et al: Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 23:7927-7935, 2005 (Pubitemid 46657392)
33. Smitt PS, Driesse M, Wolbers J, et al: Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 7:851-858, 2003 (Pubitemid 36790262)
34. Germano IM, Fable J, Gultekin SH, et al: Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: Preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 65:279-289, 2003 (Pubitemid 37526820)
35. Nestler U, Wakimoto H, Siller-Lopez F, et al: The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J Neurooncol 67:177-188, 2004 (Pubitemid 38418266)
36. Chen SH, Shine HD, Goodman JC, et al: Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 91:3054-3057, 1994 (Pubitemid 24130173)
37. Curran WJ Jr, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704-710, 1993 (Pubitemid 23133591)
38. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990 (Pubitemid 20195640)
39. Weitzner MA, Meyers CA, Gelke CK, et al: The Functional Assessment of Cancer Therapy (FACT) scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151-1161, 1995
40. Sandmair AM, Loimas S, Puranen P, et al: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11:2197-2205, 2000
41. Lang FF, Bruner JM, Fuller GN, et al: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol 21:2508-2518, 2003 (Pubitemid 46606332)
42. Chiocca EA, Abbed KM, Tatter S, et al: A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10:958-966, 2004 (Pubitemid 39419921)
43. Chiocca EA, Smith KM, McKinney B, et al: A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 16:618-626, 2008 (Pubitemid 351315003)
44. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389-2401, 2000
45. Ram Z, Culver KW, Oshiro EM, et al: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354-1361, 1997 (Pubitemid 28011035)
46. Harsh GR, Deisboeck TS, Louis DN, et al: Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathological study. J Neurosurg 92:804-811, 2000 (Pubitemid 30243929)
47. Puumalainen AM, Vapalahti M, Agrawal RS, et al: Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 9:1769-1774, 1998 (Pubitemid 28418747)
48. Immonen A, Vapalahti M, Tyynelä K, et al: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther 10:967-972, 2004 (Pubitemid 39419922)
49. Sukin SW, Chhikara M, Zhu X, et al: In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther 3:500-506, 2001 (Pubitemid 32509843)
50. Rainov NG, Fels C, Droege JW, et al: Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Ther 8:662-668, 2001 (Pubitemid 32912240)
51. Jordan JT, Sun W, Hussain, SF, et al: Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57:123-131, 2008 (Pubitemid 350043644)
52. Heimberger AB, Sun W, Hussain SF, et al: Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. Neuro Oncol 10:98-103, 2008 (Pubitemid 351250906)
53. Aguilar LK, Guzik BW, Aguilar-Cordova E: Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development. J Cell Biochem 112:1969-1977, 2011
54. Agard C, Ligeza C, Dupas B, et al: Immunedependent distant bystander effect after adenovirusmediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther 8:128-136,2001 (Pubitemid 32220977)
55. Fujita T, Teh BS, Timme TL, et al: Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 65:84-90, 2006
56. Vlachaki MT, Chhikara M, Aguilar L, et al: Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int J Radiat Oncol Biol Phys 51:1008-1017, 2001 (Pubitemid 33026432)
57. Heimberger AB, Archer GE, Mitchell DA, et al: Epidermal growth factor receptor variant III (EGFR-vIII) vaccine (CDX-110) in GBM. J Clin Oncol 27:92s, 2009 (suppl; abstr 2021)
58. Sampson JH, Heimberger AB, Archer GE, et al: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722-4729, 2010
59. Sterman DH, Recio A, Vachani A, et al: Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 11:7444-7453, 2005 (Pubitemid 41507705)
60. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010